1. Inicio
  2. Publicaciones
  3. Evolution of the use, effectiveness and safety of bismuth-containing quadruple therapy for Helicobacter pylori infection between 2013 and 2021: results from the European registry on H. pylori management (Hp-EuReg).

Evolution of the use, effectiveness and safety of bismuth-containing quadruple therapy for Helicobacter pylori infection between 2013 and 2021: results from the European registry on H. pylori management (Hp-EuReg).

Fecha de publicación: Fecha Ahead of Print:

Autores

Autores externos

  • Olmedo L
  • Calvet X
  • Gené E
  • Bordin DS
  • Voynovan I
  • Castro-Fernandez M
  • Pabón-Carrasco M
  • Keco-Huerga A
  • Perez-Aisa Á
  • Rodrigo L
  • Sarsenbaeva AS
  • Khlinov IB
  • Fadieienko G
  • Zaytsev O
  • Lanas Á
  • Martínez-Domínguez SJ
  • Alfaro E
  • Jonaitis L
  • Núñez Ó
  • Pellicano R
  • Hernández L
  • Gridnyev O
  • Kupcinskas J
  • Gasbarrini A
  • Boltin D
  • Niv Y
  • Babayeva G
  • Marcos-Pinto R
  • Tepes B
  • Venerito M
  • Papp V
  • Lerang F
  • Leja M
  • Phull PS
  • Marlicz W
  • Doulberis M
  • Smith SM
  • Milivojevic V
  • Kunovsky L
  • Mestrovic A
  • Matysiak-Budnik T
  • Simsek H
  • Cano-Català A
  • Puig I
  • Moreira L
  • Parra P
  • Nyssen OP
  • Megraud F
  • O'Morain C
  • Gisbert JP
  • Hp-EuReg investigators*

Grupos de investigación

Abstract

BACKGROUND: Bismuth quadruple therapies (BQTs) including bismuth, a proton pump inhibitor (PPI) and two antibiotics have been shown to be highly effective for treating Helicobacter pylori infection even in areas of high bacterial antibiotic resistance. OBJECTIVE: To describe the time trends of use, effectiveness and safety of BQT in Europe using the European Registry on Helicobacter pylori Management (Hp-EuReg). DESIGN: Patients registered in the Hp-EuReg from 2013 to 2021 who had received BQT were included. The regimens prescribed, the number of eradication attempts, effectiveness, adherence and safety were analysed. The effectiveness was assessed by modified intention to treat (mITT). Time-trend and multivariate analyses were performed to determine variables that predicted treatment success. RESULTS: Of the 49 690 patients included in the Hp-EuReg, 15 582 (31%) had received BQT. BQT use increased from 8.6% of all treatments in 2013 to 39% in 2021. Single-capsule BQT-containing bismuth, metronidazole and tetracycline-plus a PPI (single-capsule BQT, ScBQT) was the most frequent treatment mode (43%). Schemes that obtained an effectiveness above 90% were the 10-day ScBQT and 14-day BQT using tetracycline plus metronidazole, or amoxicillin plus either clarithromycin or metronidazole. Only ScBQT achieved above 90% cure rates in all the geographical areas studied. Using the ScBQT scheme, adherence, the use of standard or high-dose PPIs, 14-day prescriptions and the use of BQT as first-line treatment were significantly associated with higher mITT effectiveness. CONCLUSION: The use of BQT increased notably in Europe over the study period. A 10-day ScBQT was the scheme that most consistently achieved optimal effectiveness. TRIAL REGISTRATION NUMBER: NCT02328131.

© Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.

Datos de la publicación

ISSN/ISSNe:
0017-5749, 1468-3288

GUT  BMJ PUBLISHING GROUP

Tipo:
Article
Páginas:
15-25
PubMed:
39461739

Citas Recibidas en Web of Science: 25

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • ANTIBIOTIC THERAPY; HELICOBACTER PYLORI - TREATMENT; HELICOBACTER THERAPY

Campos de Estudio

Compartir